Full-Time

Manufacturing Technician

Updated on 9/3/2026

BiVACOR

BiVACOR

51-200 employees

Develops magnetically levitated total artificial heart

Compensation Overview

$28 - $34/hr

+ Annual bonus

Huntington Beach, CA, USA

In Person

Relocation benefits are not available.

Category
Manufacturing & Production Operations (1)

Get referred to BiVACOR

See people who can refer or advise you

Requirements
  • 4–7 years’ experience in electrical assembly, wire harnessing, or electromechanical manufacturing.
  • Strong experience with wiring, cable harnessing, soldering small-gauge wires, and printed circuit board work.
  • Ability to read and interpret schematics and detailed technical documentation.
  • Ability to work independently with a quality-first mindset.
  • Strong attention to detail and documentation discipline.
Responsibilities
  • Perform precision wiring, cable harnessing, crimping and fine soldering of electrical assemblies.
  • Assist with printed circuit board assembly and electrical integration of control systems.
  • Conduct in-process electrical and functional testing using in-house test equipment.
  • Troubleshoot assembly and electrical issues and support root cause investigations.
  • Support prototype builds, design verification, and validation activities alongside engineers.
  • Set up and maintain assembly and test equipment, including basic calibration and preventive maintenance.
  • Complete accurate production documentation, including device history records in compliance with Good Manufacturing Practice and Food and Drug Administration standards.
  • Mentor junior operators and maintain compliance within a cleanroom, regulated manufacturing environment.
Desired Qualifications
  • Experience within regulated industries such as medical devices or aerospace.

BiVACOR is a clinical-stage medical device company developing the BiVACOR Total Artificial Heart (TAH) to replace a failing heart. The device is a compact, titanium implant that uses a single magnetically levitated rotor to pump blood to the lungs and the rest of the body, eliminating valves and mechanical bearings to reduce blood damage. It serves as a bridge-to-transplant and aims to become a long-term (permanent) alternative to heart transplantation. BiVACOR operates in the cardiovascular medtech space, pursuing regulatory approval through preclinical and clinical trials, including an FDA Breakthrough Device Designation and an Early Feasibility Study. Its strategy includes expanding from Australia to the US, securing funding, and advancing toward commercialization to address the large unmet need in end-stage heart failure.

Company Size

51-200

Company Stage

Grant

Total Funding

$46.7M

Headquarters

Houston, Texas

Founded

2008

Get referred to BiVACOR

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Five of five U.S. patients bridged to transplant by August 2025 without pump replacement.
  • The 2026 clinical trial recruits four major centers: Duke, Banner, The Christ Hospital, Texas Heart.
  • Australia’s MRFF and NIH grants fund wireless power development and clinical expansion.

What critics are saying

  • The 15-patient expansion increases visibility; one stroke, hemolysis, or infection can halt approvals.
  • Patients need anticoagulation, transplant eligibility, and chest fit; exclusions shrink the addressable pool.
  • No commercial approval exists in 2026; late-stage trial failure would kill BiVACOR’s standalone thesis.

What makes BiVACOR unique

  • BiVACOR’s single-maglev-rotor titanium TAH removes valves, bearings, and mechanical wear points.
  • July 9, 2024 first-in-human implant and five-patient bridge-to-transplant run built credibility.
  • FDA Breakthrough Device and TAP acceptance in 2025 signal unusually close regulator engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Life Insurance

Employee Assistance Program

401(k) Company Match

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-5%

2 year growth

-9%
Wainscot Media
May 30th, 2025
Artificial Heart Receives Breakthrough Device Designation from FDA

May 30, 2025 - BiVACOR, a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), announced that its device has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

TUN
Jul 25th, 2024
Texas Heart Institute Achieves First-Ever BiVACOR Artificial Heart Implantation

The Texas Heart Institute, in collaboration with BiVACOR(R), has made a historic stride in cardiac care with the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH).

Business Wire
Feb 20th, 2024
Bivacor® Receives $13 Million To Support Clinical Trials For The Company’S Total Artificial Heart

GOLD COAST, Australia HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR®, a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements. Led by Monash University, the AHFP is comprised of a consortium of research centers in Australia in collaboration with BiVACOR. The $13 million (USD) grant comes from a larger $50 million (AUD) grant from the MRFF to the AHFP to develop and commercialize devices to treat the most common forms of severe heart failure and bring new solutions to underserved patients. The award will support clinical work of the BiVACOR Total Artificial Heart (TAH) and begin development for the integration of wireless power sources for the device

InnovationMap
Jan 8th, 2024
Houston med device company names new CEO

Jim Dillon, a longtime executive in the medical device sector, has been hired to lead BiVACOR and join its board of directors.

The Business Journals
Jan 3rd, 2024
Artificial heart company Bivacor names Jim Dillon new CEO

At the same time, Bivacor also received $3 million in Small Business Innovation Research grant funding from the National Heart, Lung, and Blood Institute at the U.S. National Institute of Health.